Close menu




October 26th, 2021 | 12:05 CEST

SAP, wallstreet:online, Alibaba: Sentiment Check for Digital Shares

  • Investments
Photo credits: pixabay.com

More and more business models are shifting to the Internet. Even traditional industries, such as trades, are benefiting from digital processes. Elsewhere, this transformation is already in full swing, such as in the financial sector. Investors have long since been trading online and only speak to their broker by phone in exceptional cases. We present three digitization stocks and examine their price potential.

time to read: 3 minutes | Author: Nico Popp
ISIN: SAP SE O.N. | DE0007164600 , WALLSTREET:ONLINE INH ON | DE000A2GS609 , ALIBABA GR.HLDG SP.ADR 8 | US01609W1027

Table of contents:


    SAP: Good business with the cloud

    SAP is a household name when it comes to enterprise software, and not just in Germany. Worldwide, SAP and Oracle share the top spot in many areas. SAP offers its software on a modular basis, enabling companies to digitize many areas gradually. The Walldorf-based company also has a lot to offer when it comes to cloud solutions. Those who offer software in the data cloud can implement updates or further developments for all customers in one fell swoop. Since the software no longer runs on the customer's premises, other pitfalls, such as incompatibilities, are also reduced. The fact that SAP is well positioned around the cloud is also shown by the list of new customers, featuring BioNTech, IKEA and Google.

    SAP has also made several strategic acquisitions in recent months and wants to make customers even happier more quickly in the future, especially with tools related to machine learning. Ideally, the technology should also detect errors before they lead to serious problems. SAP is therefore moving with the times and is constantly developing further. Among other things, this includes a cooperation with TeamViewer. Sales are expected to fall slightly due to exchange rate fluctuations. However, the fact that at least the promising cloud business is growing is a positive factor. The share has developed positively recently but is facing some resistance. Although the dividend is rising, this is not yet enough to boost the value in the long term. The stock is solid but not a must-have in the portfolio.

    wallstreet:online: Analysts see great potential

    The websites of wallstreet:online are a must - at least for committed private investors. In addition to the latest news on Finanznachrichten.de, wallstreet:online also offers discussion forums on almost every second-line stock on the portal of the same name - the site is an important source of information, especially for speculative investors. However, wallstreet:online generates its major growth with its Smartbroker. The service aims to close the gap between free brokers with a limited offering and traditional providers. So far, it has succeeded quite well - customer growth has pushed the share dynamically for months. Despite the previous gains, the share has held at a solid level between EUR 20 and 25. Where do we go from here?

    The analysts at GBC Investment Research expect sales to climb in the current fiscal year as well. Ultimately, this should justify a price target of up to EUR 37.70. Growth is expected above all from the even better dovetailing of media offerings and brokerage in the future. If investors can trade directly from websites, this should further increase the trading revenues of the Smartbroker. In addition, the broker has so far achieved its growth without a mobile app. Now such an app is to be delivered. That would make the Smartbroker attractive to some customers who trade exclusively on mobile devices. The stock is a speculative second-tier stock that has come to rest in recent weeks but that analysts say has potential. Those who believe in the bull market can bookmark wallstreet:online.

    Alibaba: One swallow does not make a spring

    A digitization share in a very special situation is Alibaba. Like its big role model, the Chinese Amazon clone has a lot of tech solutions on offer. About a year ago, the planned IPO of the fintech subsidiary ANT Group created fantasy. In the meantime, the IPO has been canceled, and ANT has been restructured. ANT and also Alibaba had come under the scrutiny of the Chinese central government because of their power. While Beijing has long supported the rise of the Internet giants, it is now trying to recapture the capitalist genie that was let out of the bottle. In the wake of the measures, many Chinese stocks went under. On top of that, China Evergrande, a real estate company, was in trouble. The bottom line is that Alibaba's stock has lost about 40% of its value in a year. Although the share has recently managed to break free, this is not yet a turnaround. In the long term, however, Alibaba should become interesting again.


    While SAP is rather dull and Alibaba still suffers from the general conditions in China, wallstreet:online can put its horsepower on the road. While the value has already risen, an intact trend has never hurt when it comes to asset accumulation. However, investors should make an investment dependent on the general development of the stock market. If the prices rise again, there should also be more private investors generating turnover at wallstreet:online.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read